ARTICLE | Strategy
Looking for signs of erosion
March 18, 2002 8:00 AM UTC
A marketing war between Biogen Inc. and Serono S.A. might expand the market for interferon-beta therapy by increasing interest in the drugs to treat relapsing-remitting multiple sclerosis (RRMS). But if the market does not expand, BGEN has the most to lose in the U.S. marketplace, as it currently holds a 56% market share...